Amarin to raise $60 million in private financing
The first $28 million tranche is expected to close shortly, subject to customary closing conditions. The investors will have an option to provide up to $28 million in

The first $28 million tranche is expected to close shortly, subject to customary closing conditions. The investors will have an option to provide up to $28 million in

Vision Partners has an organization of 84 partner dealers and 40 participating manufacturers in its network. Vision’s dealers will also provide sales and service coverage for Del imaging

The sale resulted in gross proceeds of approximately $20.2 million and net proceeds of approximately $18.8 million after offering expenses and placement agency fees. Exactech expects to use

The license includes compounds that were discovered by Scripps Research in collaboration with Poniard. The research collaboration was initiated in 2005 at Scripps Florida, a division of the

The payment will be made under the terms of the amended and restated supply agreement signed in August 2007. Stimuvax (BLP25 liposome vaccine) is an investigational therapeutic cancer

The non-exclusive license provides Stemcell with rights under certain Geron’s patents to develop, manufacture and sell cell culture media and matrix surfaces for research use only. Geron will

Progen has commenced development of PG-11047 (formerly CGC-11047), following the acquisition of Cellgate, in early 2008. The first patient to be recruited into the trial re-initiation has been

Paroxetine hydrochloride (HCl) extended-release (ER) tablet is a generic version of GlaxoSmithKline’s (GSK) Paxil CR. As the first company to successfully file an abbreviated new drug application (ANDA)

The Xtrac Velocity laser system is claimed to deliver the highest ultraviolet (UV) power of any medical excimer laser on the market today, while retaining all the reliability

Each unit shall consist of one common share and one-half share purchase warrant. Each warrant shall be exercisable, for 24 months following closing, at a price and on